AbbVie (ABBV)
(Delayed Data from NYSE)
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q2 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q2 top-line results are expected to reflect the impact of coronavirus on sales of Humira, Imbruvica and Venclexta.
Want To Retire Early? Learn the Intelligent Investing Secret - July 28, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
What Lies Ahead for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.
Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABBV) Outperforming Other Medical Stocks This Year?
3 Top Dividend Stocks to Maximize Your Retirement Income - July 27, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
How Damaging Will Coronavirus be for AbbVie (ABBV) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on AbbVie's (ABBV) performance when it reports second-quarter results.
Zacks.com featured highlights include: Quest Diagnostics, eBay, Cisco Systems, Cigna and AbbVie
by Zacks Equity Research
Zacks.com featured highlights include: Quest Diagnostics, eBay, Cisco Systems, Cigna and AbbVie
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Coronavirus-Proof GARP Stocks to Pick on Discounted PEG
by Urmimala Biswas
A lower PEG ratio, preferably less than 1, is always better for GARP investors.
Pharma Stock Roundup: NVS, RHHBY Earnings, AZN, PFE Coronavirus Vaccine Early Data
by Kinjel Shah
Pfizer (PFE) and AstraZeneca (AZN) announce early data on their coronavirus vaccine candidates. Novartis (NVS) and Roche (RHHBY) announce second-quarter results.
Signs That Your Trading Will Ruin Your Retirement - July 24, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
3 Strong Dividend Stocks to Buy Now for Income & Coronavirus Growth
by Benjamin Rains
Let's dive into three stocks that are projected to grow during the pandemic that also provide solid income through dividends...
Pfizer (PFE) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Pfizer (PFE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
AbbVie's Rinvoq Meets Late-Stage Eczema Study Endpoints
by Zacks Equity Research
AbbVie's (ABBV) JAK inhibitor, Rinvoq monotherapy achieves improvement in skin clearance and reduction in itch in significantly higher proportion of atopic dermatitis patients in a phase III study.
Gilead (GILD) to Buy 49.9% Stake in Private Cancer Drugmaker
by Zacks Equity Research
Gilead (GILD) will acquire a 49.9% stake in Tizona Therapeutics, Inc., a privately-held cancer drugmaker, for $300 million.
Glaxo, CureVac to Develop mRNA Vaccines for Infectious Disease
by Zacks Equity Research
Glaxo (GSK) signs a pact with CureVac for the development/commercialization of mRNA-based vaccines and monoclonal antibodies aimed at infectious disease pathogens.
Novartis' (NVS) Q2 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Novartis' (NVS) second-quarter 2020 sales take a hit due to the coronavirus pandemic.
Lilly's Plaque Psoriasis Candidate Meets Phase III Study Goals
by Zacks Equity Research
Lilly's (LLY) autoimmune disorder candidate, mirikizumab, superior to Cosentyx in a phase III study for patients with moderate-to-severe plaque psoriasis.
Powerful Proof Anyone Can Invest for an Early Retirement - July 20, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - July 20, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
AbbVie (ABBV) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Thematic Investing Makes Way Through the Pandemic: 5 Picks
by Sreoshi Bera
Thematic investment can help investors wade through the coronavirus-led market volatility. Here are five winning stocks.
J&J Sets in Motion Pharma Q2 Earnings: 3 Stocks to Buy
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.
What To Expect From The Crazy Earnings Season Ahead
by Daniel Laboe
Are Netflix's disappointing results a foreshadowing of what is to come from the most parabolic tech stocks this earnings season?
Should Value Investors Buy AbbVie (ABBV) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.